Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

Targeted Therapy (Investigational Antibody / ADC) (45)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type
Nogapendekin Alfa Inbakicept	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Nogapendekin Alfa Inbakicept Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vusolimogene Oderparepvec	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Vusolimogene Oderparepvec Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Bemarituzumab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Bemarituzumab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Nimotuzumab (Head & Neck)	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Nimotuzumab (Head & Neck) Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Zenocutuzumab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Zenocutuzumab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Petosemtamab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Petosemtamab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Sevabertinib	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Sevabertinib Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Zongertinib	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Zongertinib Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Trastuzumab Rezetecan	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Trastuzumab Rezetecan Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vepdegestrant	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Vepdegestrant Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Toremifene Citrate	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Toremifene Citrate Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vusolimogene	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Vusolimogene Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent

Nogapendekin Alfa Inbakicept Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vusolimogene Oderparepvec Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Bemarituzumab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Nimotuzumab (Head & Neck) Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Zenocutuzumab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Petosemtamab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Sevabertinib Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Zongertinib Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Trastuzumab Rezetecan Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vepdegestrant Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Toremifene Citrate Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Vusolimogene Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent

‹ 1 2 3 4 ›

Product Range

Company

Global Network

Products

Nogapendekin Alfa Inbakicept

Vusolimogene Oderparepvec

Bemarituzumab

Nimotuzumab (Head & Neck)

Zenocutuzumab

Petosemtamab

Sevabertinib

Zongertinib

Trastuzumab Rezetecan

Vepdegestrant

Toremifene Citrate

Vusolimogene